Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Berlin - Delayed Quote EUR

Terns Pharmaceuticals Inc (430.BE)

Compare
3.6000
+0.0400
+(1.12%)
As of 12:12:07 PM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
1,000
--
Operating Expense
99,980
102,558
62,029
50,860
37,025
Operating Income
-99,980
-102,558
-62,029
-49,860
-37,025
Net Non Operating Interest Income Expense
12,479
12,901
2,110
170
55
Other Income Expense
-303
-314
-68
40
-2,788
Pretax Income
-87,804
-89,971
-59,987
-49,650
-39,758
Tax Provision
269
239
358
508
813
Net Income Common Stockholders
-88,073
-90,210
-60,345
-50,158
-29,352
Diluted NI Available to Com Stockholders
-88,073
-90,210
-60,345
-50,158
-29,352
Basic EPS
-1.18
-1.27
-1.67
-2.21
-1.29
Diluted EPS
-1.18
-1.27
-1.67
-2.21
-1.29
Basic Average Shares
74,762.1370
71,259.2390
36,033.0450
22,705.9480
22,721.7200
Diluted Average Shares
74,762.1370
71,259.2390
36,033.0450
22,705.9480
22,721.7200
Total Operating Income as Reported
-99,980
-102,558
-62,029
-49,860
-37,025
Total Expenses
99,980
102,558
62,029
50,860
37,025
Net Income from Continuing & Discontinued Operation
-88,073
-90,210
-60,345
-50,158
-40,053
Normalized Income
-88,073
-90,210
-60,345
-50,158
-40,053
Interest Income
12,479
12,901
2,110
170
55
Net Interest Income
12,479
12,901
2,110
170
55
EBIT
-99,980
-102,558
-62,029
-49,860
-37,025
EBITDA
-99,078
-101,677
-60,997
-49,348
-36,631
Reconciled Depreciation
902
881
1,032
512
394
Net Income from Continuing Operation Net Minority Interest
-88,073
-90,210
-60,345
-50,158
-40,053
Normalized EBITDA
-99,078
-101,677
-60,997
-49,348
-36,631
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
12/31/2020 - 8/17/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NICXF Nicox S.A.
0.2400
0.00%
 
ANL Adlai Nortye Ltd.
2.2203
+0.92%
 
TRDA Entrada Therapeutics, Inc.
12.02
-0.83%
 
CGEM Cullinan Therapeutics, Inc.
8.45
-1.29%
 
IMCR Immunocore Holdings plc
30.77
+5.34%
 
MNPR Monopar Therapeutics Inc.
31.29
+0.58%
 
AGIO Agios Pharmaceuticals, Inc.
34.44
-2.13%
 
PTGX Protagonist Therapeutics, Inc.
36.15
+3.02%
 
RNA Avidity Biosciences, Inc.
29.65
+1.68%
 
ADAP Adaptimmune Therapeutics plc
0.5870
+2.51%